Videos

Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.

Brian Anderson, MD, discusses opportunities and challenges associated with integrating artificial intelligence into pathology and oncology practice.

Brian Anderson, MD, discusses opportunities and challenges associated with integrating artificial intelligence into pathology and oncology practice.

Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.

Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...

Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.

Drew Moghanaki, MD, MPH, University of California, Los Angeles, discusses whether patients with resectable lung cancer should be offered a chemo-radiation approach.

Rutika Mehta, MD, MPH, discusses how to optimize supportive care for patients with gastrointestinal cancers.

Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.